Relationship between the Japanese-style diet, gut microbiota, and dementia: a cross-sectional study

Naoki Saji (✉ sajink@nifty.com)
National Center for Geriatrics and Gerontology  https://orcid.org/0000-0003-4228-1122

Tsuyoshi Tsuduki
Tohoku University: Tohoku Daigaku

Kenta Murotani
Kurume University: Kurume Daigaku

Takayoshi Hisada
TechnoSuruga Laboratory Co. Ltd.

Taiki Sugimoto
National Center for Geriatrics and Gerontology

Ai Kimura
National Center for Geriatrics and Gerontology

Shumpei Niida
National Center for Geriatrics and Gerontology

Kenji Toba
Tokyo Metropolitan Geriatric Medical Center

Takashi Sakurai
National Center for Geriatrics and Gerontology

Research

Keywords: cognitive decline, dementia, gut microbiota, Japanese diet

DOI: https://doi.org/10.21203/rs.3.rs-255821/v1

License: ☝️ This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background

Previous studies have shown associations between the gut microbiota, microbial metabolites, and cognitive decline. However, the effect of the dietary composition on such associations has not been fully investigated.

Methods

We performed a cross-sectional sub-analysis of data from our prospective hospital-based cohort study (the Gimlet study) to evaluate the relationships between dietary composition, cognitive decline, and the gut microbiota. All the participants of the Gimlet study had been provided with information regarding this sub-study in 2018. Patients were excluded if they were unable to provide sufficient data in the questionnaire regarding their dietary composition. We assessed their demographics, dietary composition, risk factors, cognitive function, results of brain imaging, gut microbiome, and microbial metabolites. On the basis of previous studies, a nine-component traditional Japanese diet index (JDI_9), a 12-component modern JDI (JDI_12), and a 12-component revised JDI (rJDI_12), were defined. Higher JDI scores indicated greater conformity to the traditional Japanese diet. We then evaluated the relationships between the JDI scores, cognitive function, and the gut microbiome and microbial metabolites using multivariable logistic regression analyses.

Results

We analyzed data from 85 eligible patients (61% women; mean age: 74.6 ± 7.4 years; mean Mini-Mental State Examination score: 24 ± 5). Compared with participants with dementia, those without dementia were more likely to consume foods in the JDI_12, including fish and shellfish (64.5% vs. 39.1%, P = 0.048), mushrooms (61.3% vs. 30.4%, P = 0.015), soybeans and soybean-derived foods (62.9% vs. 30.4%, P = 0.013), and coffee (71.0% vs. 43.5%, P = 0.024). There were non-significant trends towards lower fecal concentrations of gut microbial metabolites in participants with a more traditional Japanese diet. Participants with dementia had lower JDI_9, JDI_12, and rJDI_12 scores than participants without dementia (dementia vs. non-dementia, median JDI_9 score: 5 vs. 7, P = 0.049; JDI_12: 7 vs. 8, P = 0.017; and rJDI_12: 7 vs. 9, P = 0.006, respectively).

Conclusions

Adherence to a traditional Japanese diet was found to be inversely associated with cognitive decline and tended to be associated with lower concentrations of gut microbial metabolites.
Trial registration:
UMIN000031851.

Background

Dementia is an important healthcare problem because 47 million people were living with dementia in 2015 [1], and the number of patients is increasing. Therefore, a comprehensive strategy for dementia research has been introduced in Japan [2]. The assessment of dementia from various viewpoints is important to improve future healthcare.

Recently, the relationship between the diet and dementia has become an intriguing research focus [3–5]. Dietary patterns such as the Mediterranean diet [3] and the Japanese diet [4, 5] are receiving a lot of attention because these can reduce the risk of dementia. Furthermore, previous studies have shown that both the Mediterranean diet [6] and the Japanese diet [7] are able to alter the gut microbiota. With respect to the Japanese dietary pattern, its characteristics are described using the Japanese diet index (JDI), which has been modified according to the findings of previous studies [8, 9]. The original index (JDI9) comprises nine components that define the traditional Japanese dietary pattern [8], but a modified index, the JDI12, has been established by the addition of three further components to the JDI9 [9]. However, recent studies have suggested that the inclusion of one component that is excluded from both the JDI9 and JDI12 may have a positive effect on cognitive function [10]. Therefore, the use of these different versions of the JDI should be compared.

Several researchers have identified associations between the gut microbiota and cognitive decline [11–13]. Previous studies have shown that dysregulation of the gut microbiome, which is characterized in the form of enterotypes, is associated with cognitive decline [12, 13]. Furthermore, bacterial products, such as gut microbial metabolites, can increase systemic inflammation [14] and are also associated with dementia [15]. According to the results of these previous studies, the gut microbiota and the microbial metabolites [16, 17] modulate host brain function via a microbiota–gut–brain axis [18]. The diversity of the gut microbiota may be an important mediator of this relationship [12], but knowledge regarding the effects of the gut microbiota and its metabolites on cognitive function remains limited.

The results of these previous studies suggest that the Japanese diet may be associated with a gut microbial composition that inhibits cognitive decline. However, the mechanism of this association has not been identified because the associations between the diet and cognitive decline, and between cognitive decline and the gut microbiota, have been analyzed separately to date. To remedy this deficiency, an analysis of the relationships that underpin the diet–microbiota–gut–brain axis is needed.

We are presently conducting a clinical study that was designed to investigate the relationship between the gut microbiota and cognitive function. In this study, we have shown that gut microbial dysregulation is cross-sectionally associated with cognitive decline [12, 13], vascular risk factors [19], and brain
magnetic resonance imaging (MRI) abnormalities [20]. Furthermore, metabolites of the gut microbiota may play important roles in these associations [15]. Therefore, we hypothesized that the consumption of a Japanese-style diet would be inversely associated with cognitive decline and that there would be an association between this diet and the gut microbiome and/or microbial metabolites.

In the present study, we aimed to evaluate the relationships between adherence to a Japanese-style diet, the gut microbiota, and cognitive decline by means of a sub-analysis of data from the ongoing clinical study. Furthermore, we aimed to evaluate the three forms of the JDI (the conventional (JDI\textsubscript{9}), updated (JDI\textsubscript{12}), and a newly-modified JDI) to determine which would show the closest relationships with cognition and the gut microbiota.

**Methods**

**Study design**

We performed a cross-sectional sub-analysis of data from a hospital-based prospective cohort study, the Gerontological Investigation of Microbiome: a Longitudinal Estimation Study (the Gimlet study), which has been conducted at the National Center for Geriatrics and Gerontology (NCGG) in Japan. Detailed information regarding the Gimlet study is provided in our previous reports [12, 13, 15]. Briefly, we enrolled patients visiting the Memory clinic at the NCGG who agreed to undergo both a medical assessment of their cognitive function and a fecal examination. The activities of daily living and cognitive function of the participants were assessed annually after their enrollment.

**Participants**

Between March 2016 and March 2017, we enrolled consecutive patients who visited the Memory clinic at the NCGG and agreed to undergo both a medical assessment of their cognitive function and a fecal examination. Participants in the Gimlet study were eligible for this sub-study if they met the following criteria: (1) they were able to undergo brain MRI and complete a questionnaire regarding their dietary composition; and (2) they provided their informed consent in writing. Patients were excluded from this sub-study if they: (1) were unable to undergo MRI and/or complete the questionnaire; or (2) they were unable to provide sufficient data in the questionnaire regarding their diet. Patients who had potential confounders and effect modifiers for the variables of interest (for example, the recent use of antibiotics) had been excluded at the time of enrollment in the Gimlet study. All the patients who had enrolled in the Gimlet study and their families had been provided with information regarding this sub-study in 2018, after their enrollment in the Gimlet study.

**Baseline assessments**

All the participants underwent a comprehensive geriatric assessment [21] that was based on the following: (1) demographic characteristics; (2) risk factors; (3) basic and instrumental activities of daily living (ADL) scales; (4) global cognitive function, assessed using the Mini-Mental State Examination
(MMSE) [22] and Clinical Dementia Rating (CDR) [23] scales; (5) neuropsychological testing; (6) behavioral and psychological symptoms; (7) assessment of the burden for caregivers; (8) depression status; (9) laboratory parameters; (10) arterial stiffness, as an indicator of arteriosclerosis [24], and the ‘impact’ of pulse [25]; and (11) the results of brain imaging, such as MRI and single-photon emission computed tomography (SPECT). All the clinical samples and data were provided by the NCGG Biobank, which collects clinical data for research.

Dietary assessments

The questionnaire regarding dietary composition consisted of 12 items. All the components of a typical Japanese diet were grouped on the basis of the definitions used in the Japanese National Health and Nutrition Survey of 2011 [26]. As in previous studies [8, 9], we identified the following 12 components of the diet: rice, miso, fish and shellfish, green and yellow vegetables, seaweed, pickles, fruit, soybeans and soybean-derived foods, mushrooms, beef and pork, chicken, green tea, and coffee. The participants and their families answered questions regarding their consumption of these items using the following options: (1) always (on 6–7 days per week), (2) usually (on 3–5 days per week), (3) sometimes (on 1–2 days per week), and (4) rarely (on <1 day per week).

Japanese dietary indices

We evaluated three Japanese dietary indices. The first was the conventional JDI (JDI$_9$) [8]: (1) for each of the seven beneficial components (rice, miso, fish and shellfish, green and yellow vegetables, seaweed, pickles, and green tea), the participants were assigned one point if their daily intake of the item was equal to or greater than the sex-specific median dietary intake; and (2) for each of the two less beneficial components (beef and pork, and coffee), the participants were assigned one point if their daily intake was below the sex-specific median intake because there are sex differences regarding the dietary intake of these items [27]. Thus, the JDI$_9$ score ranged from 0 to 9, with higher scores indicating greater conformity to the traditional Japanese diet.

The second index was defined recently [9, 28] and comprises 12 components (the JDI$_{12}$) because three further beneficial components (soybeans and soybean-derived foods, fruit, and mushrooms) had been added to the JDI$_9$. Therefore, the JDI$_{12}$ score ranged from 0 to 12, and was indicative of an expanded traditional Japanese diet. However, according to recent reports [29, 30], higher intake of coffee is associated with better health status and contributes to a lower risk of dementia. Therefore, we also defined a 12-component revised JDI (rJDI$_{12}$), in which one less beneficial component (coffee) in the JDI$_{12}$ was changed to be a beneficial component. The score of the rJDI$_{12}$, which is more representative of a modern Japanese diet, also ranged from 0 to 12 points.

Classification of cognitive function

Dementia was defined as an MMSE < 20 and/or a CDR $\geq$ 1. The participants who did not have dementia were further categorized as having mild cognitive impairment (MCI) or normal cognition (NC). MCI was
defined as an MMSE $\geq 20$ and a CDR $= 0.5$, which implies possible, very mild dementia, and suggests that the patient has a higher risk of developing dementia in the future [31]. In contrast, NC was defined as an MMSE $\geq 20$ and a CDR $= 0$.

**Brain imaging**

The participants underwent a 1.5-T MRI of their brains (Philips Ingenia, Eindhoven, the Netherlands). MRI scans were obtained, including diffusion-weighted images, fluid-attenuated inversion recovery images, T2-weighted images, T2*-weighted gradient-echo images, three-dimensional T1-weighted sagittal and axial coronal views, and 3D time-of-flight magnetic resonance angiography scans. The presence and components of cerebral small vessel disease (SVD), such as silent lacunar infarct (SLI), white matter hyperintensity (WMH), cerebral microbleeds (CMB), and enlarged periventricular space (EPVS), were categorized using previously published standards for reporting vascular changes on neuroimaging [32]. The voxel-based specific regional analysis system for Alzheimer's Disease (VSRAD) software (Eisai Co., Ltd., Tokyo, Japan) was used to quantify cortical and hippocampal atrophy, using standardized z-scores [33]. A high VSRAD score suggests the presence of Alzheimer's disease (AD) because this score reflects hippocampal atrophy, which is one of the characteristics of the brain of a patient with AD. The participants also underwent N-isopropyl-p-[\textsuperscript{123}I]-iodoamphetamine-SPECT, in which the presence of low blood flow in the area of the posterior cingulate gyrus and/or the precuneus was regarded as a surrogate marker of AD [34].

**Total SVD score**

As in a previous study [35], we rated the MRI burden of SVD on an ordinal scale from 0 to 4 by recording the presence of each of four features of cerebral SVD. This score consisted of the following: (1) SLI (1 point if present); (2) CMB (1 point if present); (3) EPVS (1 point if moderate-to-severe EPVSs are present); and (4) WMH (1 point if present).

**Gut microbiome**

Fecal samples were collected at the participants’ homes, and the samples were then frozen and stored at $-81^\circ$C at the NCGG Biobank. After all the samples had been collected, the gut microbiome of each participant was analyzed by the TechnoSuruga Laboratory (Shizuoka, Japan) using terminal restriction fragment-length polymorphism (T-RFLP) analysis [36]. The T-RFLP analysis was used to classify gut microbes into the following 10 groups: *Prevotella, Bacteroides, Lactobacillales, Bifidobacterium, Clostridium* cluster IV, *Clostridium* subcluster XIVa, *Clostridium* cluster IX, *Clostridium* cluster XI, *Clostridium* cluster XVIII, and ‘others’. By referencing the Human Fecal Microbiome T-RFLP profile [37, 38], each gut microbiome was categorized as representing one of three enterotypes: enterotype I, which included *Bacteroides* at $> 30\%$; enterotype II, which included *Prevotella* at $> 15\%$; and enterotype III, which comprised other combinations of microorganisms. The Firmicutes/Bacteroidetes (F/B) ratio was also calculated because a high ratio is indicative of dysbiosis [39].
Analysis of microbial metabolites in feces

In previous studies, the concentrations of gut microbial metabolites, including short-chain fatty acids (SCFAs) [6, 17] and lipopolysaccharide [17], have been quantified. In the present study, we measured the fecal concentrations of organic acids, SCFAs, ammonium ions, indoles, phenol, skatole, and p-cresol, as previously described [15]. The concentrations of organic acids and SCFAs (acetic acid, propionic acid, butyric acid, iso-butyric acid, succinic acid, lactic acid, formic acid, valeric acid, and iso-valeric acid) were measured using high-performance liquid chromatography. Ammonium ion concentrations were quantified using ion chromatography; and the fecal concentrations of indoles, phenol, skatole, and p-cresol were quantified using gas chromatography/mass spectrometry. Detailed information regarding the analysis of the fecal metabolites is provided in our previous report [15] and the Supplementary file.

Statistical analysis

Continuous, ordinal, and categorical variables are expressed as the mean ± standard deviation, median and interquartile range, or frequency or proportion (percentage), respectively. Data were compared using the unpaired Student’s t-test, Wilcoxon rank-sum test, and χ² test, respectively. First, the participants were allocated to groups according to the presence or absence of dementia, the presence or absence of enterotype I, and those with MCI or NC, among the participants who did not have dementia, and their clinical characteristics were compared using the Wilcoxon rank-sum test. In addition, their gut microbiomes and gut microbial metabolites were compared using the χ² test or the Wilcoxon rank-sum test. Second, we evaluated the relationships between the gut microbiome, microbial metabolites, and dietary composition. Third, the participants were allocated to two groups according to their JDI$_{12}$: a high JDI$_{12}$ group (above the median value) and a low JDI$_{12}$ group (below the median value), and we compared their clinical characteristics. We also compared the differences between participants with high rJDI$_{12}$ scores and those with low rJDI$_{12}$ scores. Finally, multivariable logistic regression models were used to identify independent associations between the presence of dementia, JDI score (JDI$_{12}$ or rJDI$_{12}$), and the gut microbiome. Odds ratios (ORs) and 95% confidence intervals (CIs) are presented. All the comparisons were two-tailed, and $P < 0.05$ was considered to represent statistical significance. Data were analyzed using the JMP 12.0 software package and SAS v9.4 (SAS Institute Inc., Cary, NC, USA).

Results

Participant characteristics

We previously enrolled 128 participants in the Gimlet study, but of these, 43 were excluded from this sub-analysis because of incomplete data and/or refusal to participate. We therefore analyzed data from the remaining 85 eligible participants (61.1% women; mean age: 74.6 ± 7.4 years; mean MMSE score: 24 ± 5). These participants were classified according to their level of cognitive function and their enterotype: 23 participants (27.1%) were classified as having dementia, 42 (49.4%) were classified as having MCI, and
20 (23.5%) were classified as having NC; 28 (32.9%) were classified as having enterotype I, 4 (4.7%) enterotype II, and 53 (62.4%) enterotype III.

Participants with dementia vs. those without

Compared with participants with dementia, those without were more likely to consume fish and shellfish (non-dementia vs. dementia, 64.5% vs. 39.1%, \( P = 0.048 \)), mushrooms (61.3% vs. 30.4%, \( P = 0.015 \)), soybeans and soybean-derived foods (62.9% vs. 30.4%, \( P = 0.013 \)), and coffee (71.0% vs. 43.5%, \( P = 0.024 \); Table 1). Although there were no significant differences, participants without dementia tended to have higher intakes of rice, noodles, miso, seaweed, fruits, beef and pork, chicken, and green tea. Participants with dementia had lower JDI scores (\( JDI_9 \), \( JDI_{12} \), and \( rJDI_{12} \)) than those without (dementia vs. non-dementia, median scores for \( JDI_9 \): 5 vs. 7, \( P = 0.049 \); \( JDI_{12} \): 7 vs. 8, \( P = 0.017 \); and \( rJDI_{12} \): 7 vs. 9, \( P = 0.006 \), respectively; Fig. 1). The \( rJDI_{12} \) score showed clearer differences in the prevalence of dementia among the participants when they were classified according to the tertile of JDI score than the \( JDI_9 \) and \( JDI_{12} \) scores (low vs. middle vs. high JDI score, according to tertile: \( JDI_9 \): 38.7% vs. 17.5% vs. 28.6%, \( P = 0.135 \); \( JDI_{12} \): 40.9% vs. 33.3% vs. 12.1%, \( P = 0.039 \); and \( rJDI_{12} \): 48.3% vs. 16.7% vs. 15.4%, \( P = 0.007 \), respectively; Fig. 2). With regard to the methods of food preparation, participants without dementia were more likely to use soup stocks than those with dementia (93.6% vs. 60.9%, \( P = 0.001 \); Table 1).
| Food                          | Dementia (+) | Dementia (-) | \( P \) |
|------------------------------|--------------|--------------|--------|
| Rice, \( n \) (%)           | 19 (82.6)    | 57 (91.9)    | 0.245 |
| Bread, \( n \) (%)          | 13 (56.5)    | 33 (53.2)    | 0.812 |
| Noodles, \( n \) (%)        | 6 (26.1)     | 23 (37.1)    | 0.443 |
| Miso, \( n \) (%)           | 12 (52.2)    | 39 (62.9)    | 0.457 |
| Fish and shellfish, \( n \) (%) | 9 (39.1)    | 40 (64.5)    | 0.048 |
| Vegetables, \( n \) (%)     | 21 (91.3)    | 58 (93.6)    | 0.660 |
| Seaweed, \( n \) (%)        | 10 (43.5)    | 32 (51.6)    | 0.627 |
| Pickles, \( n \) (%)        | 11 (47.8)    | 33 (53.2)    | 0.808 |
| Mushrooms, \( n \) (%)      | 7 (30.4)     | 38 (61.2)    | 0.015 |
| Fruit, \( n \) (%)          | 14 (60.9)    | 43 (69.4)    | 0.604 |
| Beef and pork, \( n \) (%)  | 13 (56.5)    | 46 (74.2)    | 0.184 |
| Chicken, \( n \) (%)        | 10 (43.5)    | 39 (62.9)    | 0.140 |
| Soybeans and soybean-derived foods, \( n \) (%) | 7 (30.4)    | 39 (62.9)    | 0.013 |
| Milk and dairy products, \( n \) (%) | 14 (60.9)    | 41 (66.1)    | 0.799 |
| Green tea, \( n \) (%)      | 11 (47.8)    | 41 (66.1)    | 0.140 |
| Coffee, \( n \) (%)         | 10 (43.5)    | 44 (71.0)    | 0.024 |
| Cooking method               |              |              |        |
| Boiling, \( n \) (%)        | 18 (78.3)    | 35 (56.5)    | 0.081 |
| Steaming, \( n \) (%)       | 7 (30.4)     | 22 (35.5)    | 0.799 |
| Raw, \( n \) (%)            | 12 (52.2)    | 41 (66.1)    | 0.314 |
| Deep-frying, \( n \) (%)    | 10 (43.5)    | 21 (33.9)    | 0.454 |
| Frying, \( n \) (%)         | 12 (52.2)    | 41 (66.1)    | 0.314 |

The Wilcoxon rank-sum test and the \( \chi^2 \) test were used.
|                                | Dementia (+) | Dementia (−) | \( P \) |
|--------------------------------|--------------|--------------|---------|
| \( n = 23 \)                  | \( n = 62 \) |              |         |
| Use of soup stock, \( n \) (%)| 14 (60.9)    | 58 (93.6)    | 0.001   |
| Use of fermented seasoning, \( n \) (%) | 18 (78.3) | 57 (91.9) | 0.125   |

The Wilcoxon rank-sum test and the \( \chi^2 \) test were used.

**Enterotype I vs. other enterotypes**

Compared with participants with the other enterotypes, those with enterotype I tended to consume less seaweed, fruit, and milk and dairy products, although these differences were not significant (Table S1).

**MCI vs. NC patients**

Among the participants who did not have dementia, the participants with NC tended to consume more fish, shellfish, and coffee than those with MCI, although these differences were not statistically significant (Table S2). In addition, participants with enterotype I tended to consume less miso, fish and shellfish, seaweed, fruit, chicken, and milk and dairy products, but again the differences were not statistically significant (Table S3).

**Microbial metabolites**

Participants who consumed more mushrooms (eg. higher vs. lower intake; median concentration of isobutyric acid: 0.03 vs. 0.11 mg/g, \( P = 0.017 \); Table S4), soybeans and soybean-derived foods (Table S5), or coffee (Table S6) had lower fecal concentrations of several gut microbial metabolites than those who consumed smaller amounts of these items.

**High vs. Low JDI\(_{12}\) score**

Participants with high JDI\(_{12}\) scores were less likely to be female (High vs. Low JDI\(_{12}\): 46.8\% vs. 79.0\%, \( P = 0.004 \)), less likely to have dementia (14.9\% vs. 42.1\%, \( P = 0.007 \)) and WMH (17.0\% vs. 36.8\%, \( P = 0.048 \)), had lower GDS, ZBI, and VSRAD scores, and were more likely to have good neuropsychological test results (Table 2). The concentrations of the majority of the gut microbial metabolites in participants with high JDI\(_{12}\) scores were lower than in those with low JDI\(_{12}\) scores (Table 3).
Table 2
Comparison of the characteristics of participants with JDI12 scores above or below the median value

| Demographic factor                  | High JDI12 (n = 47) | Low JDI12 (n = 38) | P  |
|-------------------------------------|---------------------|--------------------|----|
| Age, years                          | 75, 68–80           | 77, 72–81          | 0.428 |
| Female sex, n (%)                   | 22 (46.8)           | 30 (79.0)          | 0.004 |
| Education, years                    | 12, 9–13            | 12, 9–12           | 0.300 |
| Body mass index, kg/m²              | 22.4, 20.6–24.5     | 22.8, 20.6–24.8    | 0.630 |
| Systolic BP, mmHg                   | 151, 128–1,632      | 143, 123–162       | 0.221 |
| Diastolic BP, mmHg                  | 83, 72–90           | 77, 70–86          | 0.128 |
| Risk factor                          |                     |                    |    |
| Hypertension, n (%)                 | 28 (59.6)           | 25 (65.8)          | 0.654 |
| Diabetes mellitus, n (%)            | 6 (12.8)            | 5 (13.2)           | 1.000 |
| Dyslipidemia, n (%)                 | 21 (44.7)           | 23 (60.5)          | 0.191 |
| IHD, n (%)                          | 5 (10.6)            | 6 (15.8)           | 0.530 |
| Stroke, n (%)                       | 5 (10.6)            | 3 (7.9)            | 0.726 |
| CKD, n (%)                          | 15 (31.9)           | 14 (36.8)          | 0.653 |
| Smoking habit, n (%)                | 13 (27.7)           | 7 (18.4)           | 0.441 |
| Alcohol consumption, n (%)          | 21 (44.7)           | 13 (34.2)          | 0.378 |

Continuous, ordinal, and categorical variables are expressed as the mean ± standard deviation, median and interquartile range, or frequency or proportion (percentage), respectively. The Wilcoxon rank-sum test and the χ² test were used.

*Low blood flow in the area of the posterior cingulate gyrus and/or the precuneus.

Abbreviations: JDI, Japanese dietary index; BP, blood pressure; IHD, ischemic heart disease; CKD, chronic kidney disease; ApoE, apolipoprotein E; IADL, instrumental activities of daily living; DBDS, Dementia Behavior Disturbance Scale; GDS, Geriatric Depression Scale; ZBI, Zarit Caregiver Burden Interview; MNA-SF, Mini-Nutritional Assessment-Short Form; MMSE, Mini-Mental State Examination; CDR-GB, Clinical Dementia Rating Global Score; CDR-SB, Clinical Dementia Rating-Sum of Boxes; ADAS-cog, Alzheimer's Disease Assessment Scale-Cognitive Subscale; RCPM, Raven's Colored Progressive Matrices; FAB, Frontal Assessment Battery; LM-WMSR, Logical Memory subtests I and II of the Wechsler Memory Scale-Revised; SLI, silent lacunar infarct; WMH, white matter hyperintensity; CMB, cerebral microbleeds; EPVS, enlarged perivascular space; SVD, small vessel disease; VSRAD, voxel-based specific regional analysis system for Alzheimer's disease; SPECT, single-photon emission computed tomography; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate.
|                                | High JDI<sub>12</sub> | Low JDI<sub>12</sub> | \( P \) |
|--------------------------------|------------------------|-----------------------|--------|
|                                | \((n = 47)\)           | \((n = 38)\)         |        |
| APOE \(\varepsilon 4\) carrier, \(n (%)\) | 10 (21.3)              | 11 (29.0)             | 0.456  |
| Dementia, \(n (%)\)            | 7 (14.9)               | 16 (42.1)             | 0.007  |
| Frailty, \(n (%)\)             | 5 (10.6)               | 8 (21.1)              | 0.232  |
| **Comprehensive geriatric assessment** |                        |                       |        |
| Barthel index                   | 100, 100–100           | 100, 99–100           | 0.059  |
| IADL impairment, \(n (%)\)     | 15 (31.9)              | 18 (47.4)             | 0.182  |
| DBDS                            | 5, 3–11                | 9, 4–16               | 0.225  |
| GDS                             | 2, 1–4                 | 4, 2–5                | 0.057  |
| ZBI                             | 6, 3–16                | 12, 5–22              | 0.085  |
| MNA-SF                          | 13, 11–14              | 12, 11–13             | 0.269  |
| **Cognitive function**          |                        |                       |        |
| MMSE                            | 26, 22–29              | 24, 19–28             | 0.066  |
| CDR-GB                          |                        |                       | 0.025  |
| 0, \(n (%)\)                   | 12 (25.5)              | 8 (21.1)              |        |
| 0.5, \(n (%)\)                 | 33 (68.1)              | 17 (44.7)             |        |
| \(\geq 1\), \(n (%)\)         | 3 (6.4)                | 13 (34.2)             |        |
| CDR-SB                          | 1.0, 0.5–3.0           | 2.0, 0.9–5.1          | 0.036  |

Continuous, ordinal, and categorical variables are expressed as the mean ± standard deviation, median and interquartile range, or frequency or proportion (percentage), respectively. The Wilcoxon rank-sum test and the \(\chi^2\) test were used.

*Low blood flow in the area of the posterior cingulate gyrus and/or the precuneus.

Abbreviations: JDI, Japanese dietary index; BP, blood pressure; IHD, ischemic heart disease; CKD, chronic kidney disease; ApoE, apolipoprotein E; IADL, instrumental activities of daily living; DBDS, Dementia Behavior Disturbance Scale; GDS, Geriatric Depression Scale; ZBI, Zarit Caregiver Burden Interview; MNA-SF, Mini-Nutritional Assessment-Short Form; MMSE, Mini-Mental State Examination; CDR-GB, Clinical Dementia Rating Global Score; CDR-SB, Clinical Dementia Rating-Sum of Boxes; ADAS-cog, Alzheimer’s Disease Assessment Scale-Cognitive Subscale; RCPM, Raven’s Colored Progressive Matrices; FAB, Frontal Assessment Battery; LM-WMSR, Logical Memory subtests I and II of the Wechsler Memory Scale-Revised; SLI, silent lacunar infarct; WMH, white matter hyperintensity; CMB, cerebral microbleeds; EPVS, enlarged perivascular space; SVD, small vessel disease; VSRAD, voxel-based specific regional analysis system for Alzheimer’s disease; SPECT, single-photon emission computed tomography; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate.
### Table 1

| Test                        | High JDI<sub>12</sub> | Low JDI<sub>12</sub> | P   |
|-----------------------------|------------------------|----------------------|-----|
| (n = 47)                    | (n = 38)               |                      |     |
| ADAS-cog                    | 8.0, 5.0–14.0          | 11.3, 6.9–16.7       | 0.085 |
| RCPM                        | 29, 24–32              | 28, 24–30            | 0.431 |
| FAB                         | 11, 9–14               | 11, 9–13             | 0.984 |
| LM-WMSR I                   | 11, 5–18               | 7, 3–13              | 0.048 |
| LM-WMSR II                  | 5, 0–12                | 1, 0–6               | 0.033 |
| Brain MRI finding           |                        |                      |     |
| SLI, n (%)                  | 6 (12.8)               | 3 (7.9)              | 0.725 |
| WMH, n (%)                  | 8 (17.0)               | 14 (36.8)            | 0.048 |
| CMB, n (%)                  | 9 (19.2)               | 6 (15.8)             | 0.779 |
| EPVS, n (%)                 | 8 (17.0)               | 10 (26.3)            | 0.424 |
| SVD score                   | 1, 0–1                 | 0, 0–2               | 0.506 |
| VSRAD                       | 0.80, 0.57–1.30        | 1.09, 0.78–2.08      | 0.087 |
| SPECT                       |                        |                      |     |
| Low blood flow*             | 30 (65.2)              | 23 (62.2)            | 0.821 |
| Arterial stiffness          |                        |                      |     |
| Ankle brachial index        | 1.11, 1.04–1.14        | 1.12, 1.05–1.16      | 0.553 |
| Pulse wave velocity, m/s    | 18.6, 15.8–21.9        | 17.2, 14.6–19.8      | 0.159 |

Continuous, ordinal, and categorical variables are expressed as the mean ± standard deviation, median and interquartile range, or frequency or proportion (percentage), respectively. The Wilcoxon rank-sum test and the χ² test were used.

*Low blood flow in the area of the posterior cingulate gyrus and/or the precuneus.

Abbreviations: JDI, Japanese dietary index; BP, blood pressure; IHD, ischemic heart disease; CKD, chronic kidney disease; ApoE, apolipoprotein E; IADL, instrumental activities of daily living; DBDS, Dementia Behavior Disturbance Scale; GDS, Geriatric Depression Scale; ZBI, Zarit Caregiver Burden Interview; MNA-SF, Mini-Nutritional Assessment-Short Form; MMSE, Mini-Mental State Examination; CDR-GB, Clinical Dementia Rating Global Score; CDR-SB, Clinical Dementia Rating-Sum of Boxes; ADAS-cog, Alzheimer’s Disease Assessment Scale-Cognitive Subscale; RCPM, Raven’s Colored Progressive Matrices; FAB, Frontal Assessment Battery; LM-WMSR, Logical Memory subtests I and II of the Wechsler Memory Scale-Revised; SLI, silent lacunar infarct; WMH, white matter hyperintensity; CMB, cerebral microbleeds; EPVS, enlarged perivascular space; SVD, small vessel disease; VSRAD, voxel-based specific regional analysis system for Alzheimer’s disease; SPECT, single-photon emission computed tomography; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate.
| Laboratory finding | High JDI<sub>12</sub> (n = 47) | Low JDI<sub>12</sub> (n = 38) | P    |
|--------------------|-------------------------------|-------------------------------|------|
| Total protein, g/dL | 7.2, 6.9–7.6                  | 7.3, 6.9–7.6                  | 0.814|
| Albumin, g/dL       | 4.3, 4.0–4.5                  | 4.3, 4.0–4.4                  | 0.552|
| CRP, mg/dL          | 0.06, 0.02–0.18               | 0.05, 0.02–0.13               | 0.505|
| eGFR, mL/min/1.73 m<sup>2</sup> | 70.4, 55.8–74.1 | 61.2, 53.1–73.3 | 0.340|
| HbA1c, %            | 5.8, 5.6–6.2                  | 5.7, 5.6–6.0                  | 0.550|

Continuous, ordinal, and categorical variables are expressed as the mean ± standard deviation, median and interquartile range, or frequency or proportion (percentage), respectively. The Wilcoxon rank-sum test and the χ<sup>2</sup> test were used.

*Low blood flow in the area of the posterior cingulate gyrus and/or the precuneus.

Abbreviations: JDI, Japanese dietary index; BP, blood pressure; IHD, ischemic heart disease; CKD, chronic kidney disease; ApoE, apolipoprotein E; IADL, instrumental activities of daily living; DBDS, Dementia Behavior Disturbance Scale; GDS, Geriatric Depression Scale; ZBI, Zarit Caregiver Burden Interview; MNA-SF, Mini-Nutritional Assessment-Short Form; MMSE, Mini-Mental State Examination; CDR-GB, Clinical Dementia Rating Global Score; CDR-SB, Clinical Dementia Rating-Sum of Boxes; ADAS-cog, Alzheimer's Disease Assessment Scale-Cognitive Subscale; RCPM, Raven's Colored Progressive Matrices; FAB, Frontal Assessment Battery; LM-WMSR, Logical Memory subtests I and II of the Wechsler Memory Scale-Revised; SLI, silent lacunar infarct; WMH, white matter hyperintensity; CMB, cerebral microbleeds; EPVS, enlarged perivascular space; SVD, small vessel disease; VSRAD, voxel-based specific regional analysis system for Alzheimer's disease; SPECT, single-photon emission computed tomography; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate.
Table 3
Comparison of the gut microbiome and fecal microbial metabolite concentrations of participants with JDI12 scores above or below the median value

|                      | High JDI\textsubscript{12} (n = 47) | Low JDI\textsubscript{12} (n = 38) | \( P \) |
|----------------------|-------------------------------------|-----------------------------------|--------|
| Gut microbiome       |                                     |                                   | 0.716  |
| Enterotype I, \( n \) (%) | 15 (34.2)                           | 13 (34.1)                         |        |
| Enterotype II, \( n \) (%) | 3 (6.4)                             | 1 (2.6)                           |        |
| Enterotype III, \( n \) (%) | 29 (61.7)                           | 24 (63.2)                         |        |
| F/B ratio            | 1.50, 0.82–2.70                     | 1.84, 1.11–3.12                   | 0.147  |
| Metabolite           |                                     |                                   |        |
| Ammonia, mg/g        | 0.64, 0.37–0.98                     | 0.58, 0.24–0.94                   | 0.431  |
| Succinic acid, mg/g  | 0.03, 0.03–0.10                     | 0.03, 0.03–0.44                   | 0.622  |
| Lactic acid, mg/g    | 0.03, 0.03–0.10                     | 0.03, 0.03–0.58                   | 0.398  |
| Formic acid, mg/g    | 0.05, 0.05–0.05                     | 0.05, 0.05–0.05                   | 0.282  |
| Acetic acid, mg/g    | 2.27, 0.03–6.09                     | 2.91, 0.03–6.84                   | 0.741  |
| Propionic acid, mg/g | 0.23, 0.03–1.51                     | 0.84, 0.03–2.46                   | 0.206  |
| Iso-butyric acid, mg/g | 0.06, 0.03–0.19                   | 0.07, 0.03–0.15                   | 0.669  |
| n-butyric acid, mg/g | 0.13, 0.03–0.86                     | 0.29, 0.03–0.88                   | 0.863  |
| Iso-valeric acid, mg/g | 0.03, 0.03–0.38                   | 0.03, 0.03–0.25                   | 0.347  |
| n-valeric acid, mg/g | 0.24, 0.03–1.95                     | 0.17, 0.03–2.61                   | 0.639  |
| Phenol, \( \mu g/g \) | 1.02, 0.0003–1.93                   | 1.16, 0.0003–2.12                 | 0.495  |
| P-cresol, \( \mu g/g \) | 0.32, 0.0003–118.07                | 0.24, 0.0003–15.27                | 0.213  |
| 4-Ethylphenol, \( \mu g/g \) | 0.26, 0.0003–0.91                  | 0.0003, 0.0003–0.66               | 0.110  |
| Indoles, \( \mu g/g \) | 1.79, 0.14–25.57                   | 1.06, 0.0003–22.53                | 0.728  |
| Skatole, \( \mu g/g \) | 0.11, 0.0003–5.79                   | 0.0003, 0.0003–0.17               | 0.033  |

The Wilcoxon rank-sum test and the \( \chi^2 \) test were used.

**High vs. Low rJDI\textsubscript{12} score**
Participants with high rJDI$_{12}$ scores were less likely to be female, less likely to have dementia (High vs. Low rJDI$_{12}$: 15.0% vs. 37.8%, $P = 0.027$) and WMH (12.5% vs. 37.8%, $P = 0.012$), had lower ZBI (5 vs. 14 points, $P = 0.010$) and VSRAD (median score; 0.74 vs. 1.15, $P = 0.031$) scores, and were more likely to have good neuropsychological test results (Table S7). In addition, the fecal concentrations of the majority of the gut microbial metabolites in participants with high rJDI$_{12}$ scores were lower than in those with low rJDI$_{12}$ scores (Table S8).

**Results of multivariate analyses**

In univariable analyses, greater intakes of fish and shellfish (OR, 95% CI; 0.35, 0.13–0.93, $P = 0.036$), mushrooms (0.28, 0.09–0.75, $P = 0.011$), soybeans and soybean-derived foods (0.26, 0.09–0.70, $P = 0.007$), and coffee (0.31, 0.11–0.84, $P = 0.021$) were associated with significantly lower ORs for dementia (Table S9), as was the use of soup stock (0.32, 0.03–0.38, $P = 0.001$). However, there were no significant differences in univariable analyses for the presence of enterotype I (Table S10).

In multivariable analyses, participants with high JDI$_{12}$ scores were inversely associated with the presence of dementia and were significantly associated with lower ORs (Table 4). The increment in both JDI$_{12}$ and rJDI$_{12}$ scores (per one point increment) were also inversely associated with the presence of dementia and were associated with lower ORs; however, there were no significant differences in the stepwise multivariable logistic regression analyses (Table S11). The area under the receiver operating curve (AUC) of rJDI$_{12}$ for the presence of dementia was the highest among those of the three JDI indices (AUC for JDI$_9$: 0.637; JDI$_{12}$: 0.668; and rJDI$_{12}$: 0.693).
|                                      | OR   | 95% CI     | $P$  |
|--------------------------------------|------|------------|------|
| **High JDI$_9$ score (vs. Low score) * |      |            |      |
| Model 1                              | 0.41 | 0.15–1.08  | 0.070|
| Model 2                              | 0.48 | 0.17–1.38  | 0.175|
| Model 3                              | 0.59 | 0.18–1.94  | 0.384|
| Model 4                              | 0.36 | 0.12–1.03  | 0.057|
| **High JDI$_{12}$ score (vs. Low score) * |      |            |      |
| Model 1                              | 0.24 | 0.08–0.65  | 0.005|
| Model 2                              | 0.33 | 0.11–0.97  | 0.043|
| Model 3                              | 0.22 | 0.07–0.66  | 0.006|
| Model 4                              | 0.10 | 0.01–0.45  | 0.002|
| **High rJDI$_{12}$ score (vs. Low score) * |      |            |      |
| Model 1                              | 0.29 | 0.09–0.80  | 0.016|
| Model 2                              | 0.36 | 0.11–1.06  | 0.064|
| Model 3                              | 0.34 | 0.10–1.10  | 0.072|
| Model 4                              | 0.34 | 0.07–1.32  | 0.120|

*Allocated to two groups according to their JDI: a high JDI$_{12}$ group (above the median value) and a low JDI group (below the median value).

Abbreviations: OR, odds ratio; CI, confidence interval; JDI, Japanese dietary index. The dependent variable was the presence of dementia. JDI$_9$: conventional JDI score, which comprised seven beneficial components (“rice”, “miso”, “fish and shellfish”, “green and yellow vegetables”, “seaweed”, “pickles”, and “green tea”), and two less beneficial components (“beef and pork” and “coffee”); 0–9 points. JDI$_{12}$: modified JDI score, comprising the JDI$_9$ components and three additional beneficial components (“soybeans and soybean-derived foods”, “fruit”, and “mushrooms”); 0–12 points. r-JDI$_{12}$: revised JDI$_{12}$ score, in which one less beneficial component (“coffee”) in the JDI$_{12}$ was changed to a beneficial component, such that these became “rice”, “miso”, “fish and shellfish”, “green and yellow vegetables”, “seaweed”, “pickles”, “green tea” and “coffee”; and there was just one less beneficial component (“beef and pork”), making it more consistent with the modern Japanese diet; 0–12 points.
Model 1: univariate analyses. Model 2: adjusted for age, sex. Model 3: backward stepwise multivariable logistic regression analyses, which were adjusted for the model 2 factors, years of education, and risk factors (hypertension, dyslipidemia, diabetes mellitus, ischemic heart disease, chronic kidney disease, smoking, alcohol consumption, and ApoE). Model 4: backward stepwise multivariable logistic regression analyses adjusted for the factors in model 3, plus enterotype I, silent lacunar infarct, white matter hyperintensity, cerebral microbleeds, enlarged perivascular space, score of the voxel-based specific regional analysis system for Alzheimer’s disease, single-photon emission-computed tomography findings (presence or absence of low blood flow in the area of the posterior cingulate gyrus and/or precuneus), ankle brachial index, and pulse wave velocity.

| OR | 95% CI | P |
|----|--------|---|

Discussion

The main finding of the present study is that adherence to a traditional Japanese diet was inversely associated with cognitive decline and tended to be associated with low concentrations of several gut microbial metabolites. Associations between adherence to a traditional Japanese diet and cognitive decline have previously been reported in community-dwelling older people [4, 5, 40] and in younger adults [41]. However, this relationship had not previously been evaluated in older adults in a hospital-based cohort. Therefore, our findings are novel in this respect. Such associations among diet, clinical data, the gut microbiome, and microbial metabolites had not been previously reported.

Traditional Japanese diets include large amounts of fish and shellfish, miso, seaweed, vegetables, soy products, fruit, and green tea [40, 42], and some of these (fish, vegetables, soy products, and fruit) are associated with beneficial effects on cognitive function [40, 42–44]. In the present study, we found that greater intake of these foods was inversely associated with cognitive decline in univariate analyses and tended to be associated with lower fecal concentrations of specific gut microbial metabolites. These findings are consistent with those of previous studies.

The assessment of dietary patterns using the JDI\textsubscript{12} and rJDI\textsubscript{12} yielded similar results in the present study. However, the rJDI\textsubscript{12} showed more clearly that the consumption of larger amounts of four foods (soybeans and soybean-derived foods, fruit, mushrooms, and coffee) was associated with a lower OR for the presence of dementia. Therefore, these foods likely make the largest contribution to the association between diet and dementia.

The Japanese dietary pattern shares characteristics with the Mediterranean diet; for instance, the high intake of vegetables, legumes, and fish, and the low consumption of meat [42]. Therefore, the mechanism underlying the association between adherence to a Japanese-style diet and the lower risk of dementia may be similar to that reported following studies of the Mediterranean diet. Specifically, the Mediterranean diet affects the composition of the gut microbiota and the concentrations of the derived metabolites, and is associated with improvements in biomarkers of AD [6].

In particular, we found that mushroom and soybean consumption was associated with lower ORs for the presence of dementia. Mushrooms and soybeans contain many useful nutrients, such as dietary fiber,
minerals, B vitamins, vitamin D, and vitamin E [44, 45]. Furthermore, mushroom consumption alters lipid metabolism, and has anti-obesity, anti-atherosclerotic, and anti-diabetic effects [45]. In addition, soybeans contain phytoestrogens (isoflavones), which have beneficial effects on cognitive function [44]. This is consistent with both JDI_{12} and rJDI_{12} being inversely associated with the presence of dementia.

Milk and dairy products are considered to be beneficial for health. Previous studies have shown that the consumption of milk and dairy products is associated with better mental health [46] and a lower risk of dementia [5, 47] in older adults, but there was insufficient evidence regarding its relationship with cognitive function to draw a conclusion in a previous meta-analysis [48]. In the present study, a significant relationship between dementia and the consumption of milk and dairy products was also not identified.

The relationships between the consumption of green tea and coffee and cognitive function are also unclear. One previous study showed that the consumption of green tea prevents oxidative stress, but may not significantly affect cognitive function in older adults [49], and another showed that green tea, but not coffee, reduces the risk of cognitive decline in older adults [50]. It has also been reported that caffeine consumption, and especially the moderate quantities consumed in coffee or green tea, reduces the risk of dementia [10], probably because caffeine affects neural and vascular activity, including vasoconstriction and cerebral blood flow [10]. In the present study, there was no significant association between green tea consumption and dementia, but greater intake of coffee tended to be associated with lower concentrations of microbial metabolites that are associated with dementia. This trend will be investigated further in the future.

Polyunsaturated fatty acid [51] and probiotic [52] consumption have been shown to ameliorate or preserve cognitive function. Previous studies have suggested that intake of the probiotics *Bifidobacterium* [52] or *Lactobacillus* [53] inhibits cognitive decline. Dietary diversity is also protective against cognitive decline [54], and nutritional education [55] is essential for patients and their family members. In the present study, the effects of soup stock on the gut microbiota and cognitive function were unclear, and these relationships will be investigated in more detail in the future.

The present study had several strengths. First, we have provided evidence for novel relationships between the Japanese dietary indices, the gut microbiota, and cognitive decline, which are consistent with the existence of a diet–microbiome–gut–brain axis. Specifically, adherence to a traditional Japanese diet is associated with low fecal concentrations of specific gut microbial metabolites. Moreover, increments in the JDI scores are associated with decreases in the prevalence of dementia. Second, we systematically assessed the cognitive function of patients using a comprehensive geriatric assessment and a range of neuro-psychological tests. Last, our findings may lead to greater attention being paid to the relationships between the composition of the diet and cognitive function, through assessment of the gut microbiome.

The present study also had several limitations. A causal relationship between the gut microbiome and dietary pattern could not be identified because of the cross-sectional nature of the study. We are currently
conducting a longitudinal observational study that will help us identify causality in these relationships in the near future. In addition, other research groups are conducting randomized, placebo controlled, double-blind clinical studies regarding the links between the gut microbiota and cognition using antioxidant or probiotic supplements [56, 57]. The small number of participants and large number of potential variables in the present study mean that it may have been statistically underpowered; a larger-scale study might have yielded significant findings where we only identified trends. In addition, selection bias may also exist because we studied a single, hospital-based cohort. We could not quantitatively evaluate dietary intake, and frequency evaluation is unable to determine the dose-dependency of the relationships. The specific effects of each microbial metabolite have not been determined. However, there have been recent studies of the associations between metabolites and cognitive function [16, 17, 58], and those findings will be complemented by others in the future that will clarify the nature of such relationships. Measurement of the concentration of amyloid-β precursor protein may be also useful because it is associated with the risk of cognitive impairment [59].

Although the present sub-study was of a small number of patients, which renders the analysis preliminary, our findings provide evidence for relationships between the Japanese dietary pattern, the gut microbiota, and cognitive function. Longitudinal assessments of these relationships should be made in future studies to determine the underlying mechanisms involved.

Conclusions
Adherence to a traditional Japanese diet was inversely associated with cognitive decline and tended to be associated with lower concentrations of several microbial metabolites in an older Japanese population.

Declarations

Ethics approval and consent to participate
This study was conducted in accordance with the principles of the Declaration of Helsinki and was approved by the Institutional Review Board of the NCGG (no. 1191-3). Written informed consent was obtained from all the patients and their families before their participation in this study. The Gimlet study is registered with the UMIN Clinical Trials Registry (UMIN000031851).

Consent for publication
Not applicable.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests
Dr Saji has received a Grant-in-Aid for Scientific Research (C), JSPS KAKENHI (20k07861), the NARO Bio-oriented Technology Research Advancement Institution Project (Advanced Integration Research for Agriculture and Interdisciplinary Fields), the Danone Institute of Japan Foundation, the Honjo International Scholarship Foundation, and the BMS/Pfizer Japan Thrombosis Investigator-initiated Research Program. Dr Saji, Dr Niida, and Dr Sakurai have received research grants from the Research Funding of Longevity Sciences from the National Center for Geriatrics and Gerontology. Dr Saji, Dr Toba, Dr Niida, and Dr Sakurai have received research funding for Comprehensive Research on Aging and Health from the Japan Agency for Medical Research and Development (AMED). Dr Tsuduki has received grants from the NARO Bio-oriented Technology Research Advancement Institution Project (Advanced Integrative Research for Agriculture and Interdisciplinary Fields).

**Funding**

This study was supported by a Grant-in-Aid for Scientific Research (C), JSPS KAKENHI (20k07861), grants from the Research Funding of Longevity Sciences and the NCGG (19-24), the NARO Bio-oriented Technology Research Advancement Institution Project (Advanced Integration Research for Agriculture and Interdisciplinary Fields), the Danone Institute of Japan Foundation, and the Honjo International Scholarship Foundation.

**Author's contributions**

NS was the principal investigator and contributed to the concept, design of the protocol, analyzed the data, and wrote the manuscript. TT analyzed the data and reviewed the manuscript. KM, TH, TS, AK, SN, KT, and TS reviewed the manuscript and made constructive suggestions. All the authors read and approved the final version of the manuscript.

**Acknowledgements**

We would like to thank Yukie Ohsaki, Maki Yamamoto, Hana Saito, and Ayaka Suzuki (NCGG) for their technical and secretarial assistance. We also thank the BioBank and NCGG for the quality control of the clinical samples and data. Finally, we thank Mark Cleasby, PhD, from Edanz Group (https://en-author-services.edanz.com/ac) for editing a draft of this manuscript.

**Abbreviations**

JDI: Japanese diet index.

**References**

1. Livingston G, Sommerlad A, Orgeta V, Costafreda SG, Huntley J, Ames D, et al. Dementia prevention, intervention, and care. Lancet. 2017;390:2673–734.
2. Saji N, Sakurai T, Suzuki K, Mizusawa H, Toba K; ORANGE investigators. ORANGE’s challenge: developing wide-ranging dementia research in Japan. Lancet Neurol. 2016;15:661–2.

3. Psaltopoulou T, Sergentanis TN, Panagiotakos DB, Sergentanis IN, Kosti R, Scarmeas N. Mediterranean diet, stroke, cognitive impairment, and depression: A meta-analysis. Ann Neurol. 2013;74:580–91.

4. Tomata Y, Sugiyama K, Kaiho Y, Honkura K, Watanabe T, Zhang S, et al. Dietary Patterns and Incident Dementia in Elderly Japanese: The Ohsaki Cohort 2006 study. J Gerontol A: Biol Sci Med Sci. 2016;71:1322–8.

5. Ozawa M, Ninomiya T, Ohara T, Doi Y, Uchida K, Shirota T, et al. Dietary patterns and risk of dementia in an elderly Japanese population: the Hisayama Study. Am J Clin Nutr. 2013;97:1076–82.

6. Nagpal R, Neth BJ, Wang S, Craft S, Yadav H. Modified Mediterranean-ketogenic diet modulates gut microbiome and short-chain fatty acids in association with Alzheimer’s disease markers in subjects with mild cognitive impairment. 2019;47:529–42.

7. Kushida M, Sugawara S, Asano M, Yamamoto K, Fukuda S, Tsuduki T. Effects of the 1975 Japanese diet on the gut microbiota in younger adults. J Nutr Biochem. 2019;64:121–7.

8. Tomata Y, Watanabe T, Sugawara Y, Chou WT, Kakizaki M, Tsuji I. Dietary patterns and incident functional disability in elderly Japanese: the Ohsaki Cohort 2006 study. J Gerontol A Biol Sci Med Sci. 2014;69:843–51.

9. Zhang S, Otsuka R, Tomata Y, Shimokata H, Tange C, Tomida M, et al. A cross-sectional study of the associations between the traditional Japanese diet and nutrient intakes: the NILS-LSA project. Nutr J. 2019;18:43.

10. Chen JQA, Scheltens P, Groot C, Ossenkoppele R. Associations between Caffeine Consumption, Cognitive Decline, and Dementia: A Systematic Review. J Alzheimers Dis, 2020;78:1519–46.

11. Vogt NM, Kerby RL, Dill-McFarland KA, Harding SJ, Merluzzi AP, Johnson SC, et al. Gut microbiome alterations in Alzheimer’s disease. Sci Rep. 2017;7:13537.

12. Saji N, Niida S, Murotani K, Hisada T, Tsuduki T, Sugimoto T, et al. Analysis of the relationship between the gut microbiome and dementia: a cross-sectional study conducted in Japan. Sci Rep. 2019;9:1008.

13. Saji N, Murotani K, Hisada T, Tsuduki T, Sugimoto T, Kimura A, et al. The relationship between the gut microbiome and mild cognitive impairment in patients without dementia: A cross-sectional study conducted in Japan. Sci Rep. 2019;9:19227.

14. Tang WH, Kitai T, Hazen SL. Gut Microbiota in Cardiovascular Health and Disease. Circ Res. 2017;120:1183–96.

15. Saji N, Murotani K, Hisada T, Kunihiro T, Tsuduki T, Sugimoto T, et al. Relationship between dementia and gut microbiome-associated metabolites: a cross-sectional study in Japan. Sci Rep. 2020;10:8088.

16. Moreno-Arribas MV, Bartolomé B, Peñalvo JL, Pérez-Matute P, Motilva MJ. Relationship between Wine Consumption, Diet and Microbiome Modulation in Alzheimer’s Disease. Nutrients. 2020;12:3082.
17. Wu L, Han Y, Zheng Z, Peng G, Liu P, Yue S, et al. Altered Gut Microbial Metabolites in Amnestic Mild Cognitive Impairment and Alzheimer’s Disease: Signals in Host-Microbe Interplay. Nutrients. 2021;13:228.

18. Wu SC, Cao ZS, Chang KM, Juang JL. Intestinal microbial dysbiosis aggravates the progression of Alzheimer’s disease in Drosophila. Nat Commun. 2017;8:24.

19. Saji N, Hisada T, Tsuduki T, Niida S, Toba K, Sakurai T. Proportional changes in the gut microbiome: a risk factor for cardiovascular disease and dementia? Hypertens Res. 2019;42:1090–1.

20. Saji N, Murotani K, Hisada T, Tsuduki T, Sugimoto T, Kimura A, et al. The Association between Cerebral Small Vessel Disease and the Gut Microbiome: A Cross-Sectional Analysis. J Stroke Cerebrovasc Dis. 2021;30:105568.

21. Toba K. The guideline for comprehensive geriatric assessment. Nihon Ronen Igakkai Zasshi. 2005;42:177–80.

22. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–98.

23. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412–4.

24. Saji N, Kimura K, Yagita Y, Kawarai T, Shimizu H, Kita Y. Comparison of arteriosclerotic indicators in patients with ischemic stroke: ankle-brachial index, brachial-ankle pulse wave velocity and cardioankle vascular index. Hypertens Res. 2015;38:323–8.

25. Saji N, Toba K, Sakurai T. Cerebral Small Vessel Disease and Arterial Stiffness: Tsunami effect in the brain? Pulse. 2016;3:182–9.

26. Ministry of Health, Labour and Welfare. Japan National Health and Nutrition Survey 2011. Tokyo. 2013.

27. D’Amico D, Parrott MD, Greenwood CE, Ferland G, Gaudreau P, Belleville S, et al. Sex differences in the relationship between dietary pattern adherence and cognitive function among older adults: Findings from the Nuage study. Nutr J. 2020;19:58.

28. Suzuki N, Goto Y, Ota H, Kito K, Mano F, Joo E, et al. Characteristics of the Japanese Diet Described in Epidemiologic Publications: A Qualitative Systematic Review. J Nutr Sci Vitaminol. 2018;64:129–37.

29. Liu QP, Wu YF, Cheng HY, Xia T, Ding H, Wang H, et al. Habitual coffee consumption and risk of cognitive decline/dementia: A systematic review and meta-analysis of prospective cohort studies. Nutrition. 2016;32:628–36.

30. Abe SK, Saito E, Sawada N, Tsugane S, Ito H, Lin Y, et al. Coffee consumption and mortality in Japanese men and women: A pooled analysis of eight population-based cohort studies in Japan (Japan Cohort Consortium). Prev Med. 2019;123:270–7.

31. Perneczky R, Wagenpfeil S, Komossa K, Grimmer T, Diehl J, Kurz A. Mapping scores onto stages: mini-mental state examination and clinical dementia rating. Am J Geriatr Psychiatry. 2006;14:139–44.
32. Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013;12:822–38.

33. Matsuda H, Mizumura S, Nemoto K, Yamashita F, Imabayashi E, Sato N, et al. Automatic voxel-based morphometry of structural MRI by SPM8 plus diffeomorphic anatomic registration through exponentiated lie algebra improves the diagnosis of probable Alzheimer Disease. AJNR Am J Neuroradiol. 2012;33:1109–14.

34. Ito K, Mori E, Fukuyama H, Ishii K, Washimi Y, Asada T, et al. Prediction of outcomes in MCI with (123)I-IMP-CBF SPECT: a multicenter prospective cohort study. Ann Nucl Med. 2013;27:898–906.

35. Staals J, Makin SD, Doubal FN, Dennis MS, Wardlaw JM. Stroke subtype, vascular risk factors, and total MRI brain small-vessel disease burden. Neurology. 2014;83:1228–34.

36. Osborn AM, Moore ER, Timmis KN. An evaluation of terminal-restriction fragment length polymorphism (T-RFLP) analysis for the study of microbial community structure and dynamics. Environ Microbiol. 2000;2:39–50.

37. Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, et al. Enterotypes of the human gut microbiome. Nature. 2011;473:174–80.

38. Emoto T, Yamashita T, Sasaki N, Hirota Y, Hayashi T, So A, et al. Analysis of Gut Microbiota in Coronary Artery Disease Patients: A Possible Link between Gut Microbiota and Coronary Artery Disease. J Atheroscler Thromb. 2016;23:908–21.

39. Spychala MS, Venna VR, Jandzinski M, Doran SJ, Durgan DJ, Ganesh BP, et al. Age-related changes in the gut microbiota influence systemic inflammation and stroke outcome. Ann Neurol. 2018;84:23–36.

40. Okubo H, Inagaki H, Gondo Y, Kamide K, Ikebe K, Masui Y, et al. Association between dietary patterns and cognitive function among 70-year-old Japanese elderly: a cross-sectional analysis of the SONIC study. Nutr J. 2017;16:56.

41. Sugawara S, Kushida M, Iwagaki Y, Asano M, Yamamoto K, Tomata Y, et al. The 1975 type Japanese Diet Improves Lipid Metabolic Parameters in Younger Adults: A Randomized Controlled Trial. J Oleo Sci. 2018;67:599–607.

42. Matsuyama S, Zhang S, Tomata Y, Abe S, Tanji F, Sugawara Y, Tsuji I. Association between improved adherence to the Japanese diet and incident functional disability in older people: The Ohsaki Cohort 2006 study. Clin Nutr. 2020;39:2238–45.

43. Tsurumaki N, Zhang S, Tomata Y, Abe S, Sugawara Y, Matsuyama S, et al. Fish consumption and risk of incident dementia in elderly Japanese: The Ohsaki cohort 2006 study. Br J Nutr. 2019;122:1182–91.

44. Nakamoto M, Otsuka R, Nishita Y, Tange C, Tomida M, Kato Y, et al. Soy food and isoflavone intake reduces the risk of cognitive impairment in elderly Japanese women. Eur J Clin Nutr. 2018;72:1458–62.
45. Shimizu T, Mori K, Kobayashi H, Tsuduki T. Japanese mushroom consumption alters the lipid metabolomic profile of high-fat diet-fed mice. Heliyon. 2020;6:e04438.

46. Choda N, Wakai K, Naito M, Imaeda N, Goto C, Maruyama K, et al. Associations between diet and mental health using the 12-item General Health Questionnaire: cross-sectional and prospective analyses from the Japan Multi-Institutional Collaborative Cohort Study. Nutr J. 2020;19:2.

47. Otsuka R, Kato Y, Nishita Y, Tange C, Nakamoto M, Tomida M, et al. Cereal Intake Increases and Dairy Products Decrease Risk of Cognitive Decline among Elderly Female Japanese. J Preve Alzheimers Dis. 2014;1:160–7.

48. Lee J, Fu Z, Chung M, Jang D-J, Lee H-J. Role of milk and dairy intake in cognitive function in older adults: A systematic review and meta-analysis. Nutr J. 2018;17:82.

49. Ide K, Yamada H, Takuma N, Kawasaki Y, Harada S, Nakase J, et al, Effects of green tea consumption on cognitive dysfunction in an elderly population: a randomized placebo-controlled study. Nutr J. 2016;15:49.

50. Shirai Y, Kuriki K, Otsuka R, Kato Y, Nishita Y, Tange C, et al. Green tea and coffee intake and risk of cognitive decline in older adults: the National Institute for Longevity Sciences, Longitudinal Study of Aging. Public Health Nutr. 2020;23:1049–57.

51. Dong X, Li S, Chen J, Li Y, Wu Y, Zhang D. Association of dietary ω-3 and ω-6 fatty acids intake with cognitive performance in older adults: National Health and nutrition examination Survey (NHANES) 2011–2014. Nutr J. 2020;19:25.

52. Xiao J, Katsumata N, Bernier F, Ohno K, Yamauchi Y, Odamaki T, et al. Probiotic Bifidobacterium breve in Improving Cognitive Functions of Older Adults with Suspected Mild Cognitive Impairment: A Randomized, Double-Blind, Placebo-Controlled Trial. J Alzheimers Dis, 2020;77:139–47.

53. Hwang YH, Park S, Paik JW, Chae SW, Kim DH, Jeong DG, et al. Efficacy and Safety of Lactobacillus Plantarum C29-Fermented Soybean (DW2009) in Individuals with Mild Cognitive Impairment: A 12-week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Nutrients. 2019;11:305.

54. Otsuka R, Nishita Y, Tange C, Tomida M, Kato Y, Nakamoto M, et al. Dietary diversity decreases the risk of cognitive decline among Japanese older adults. Geriatr Gerontol Int. 2017;17:937–44.

55. Pivi GA, da Silva RV, Juliano Y, Novo NF, Okamoto IH, Brant CQ, et al. A prospective study of nutrition education and oral nutritional supplementation in patients with Alzheimer’s disease. Nutr J. 2011;10:98.

56. Simpson T, Deleuil S, Echeverria N, Komanduri M, Macpherson H, Suo C, et al. The Australian Research Council Longevity Intervention (ARCLI) study protocol (ANZCTR12611000487910) addendum: Neuroimaging and gut microbiota protocol. Nutr J. 2019;18:1.

57. Karakula-Juchnowicz H, Rog J, Juchnowicz D, Łoniewski I, Skonieczna-Żydecka K, Krukow P, et al. The study evaluating the effect of probiotic supplementation on the mental status, inflammation, and intestinal barrier in major depressive disorder patients using gluten-free or gluten-containing diet...
(SANGUT study): a 12-week, randomized, double-blind, and placebo-controlled clinical study protocol. Nutr J. 2019;18:50.

58. Koszewicz M, Jaroch J, Brzecka A, Ejma M, Budrewicz S, Mikhaleva LM, et al. Dysbiosis is one of the risk factor for stroke and cognitive impairment and potential target for treatment. Pharmacol Res. 2021;164:105277.

59. Saji N, Tone S, Murotani K, Yagita Y, Kimura K, Sakurai T. Cilostazol May Decrease Plasma Inflammatory Biomarkers in Patients with Recent Small Subcortical Infarcts: A Pilot Study. J Stroke Cerebrovasc Dis. 2018;27:1639-45.

Tables
Table 1. Comparison of dietary composition between participants with dementia and those without

|                | Dementia (+) | Dementia (−) | $P$  |
|----------------|--------------|--------------|------|
| **Food**       | (n = 23)     | (n = 62)     |      |
| Rice, $n$ (%)  | 19 (82.6)    | 57 (91.9)    | 0.245|
| Bread, $n$ (%) | 13 (56.5)    | 33 (53.2)    | 0.812|
| Noodles, $n$ (%) | 6 (26.1) | 23 (37.1)    | 0.443|
| Miso, $n$ (%)  | 12 (52.2)    | 39 (62.9)    | 0.457|
| Fish and shellfish, $n$ (%) | 9 (39.1) | 40 (64.5)    | 0.048|
| Vegetables, $n$ (%) | 21 (91.3) | 58 (93.6)    | 0.660|
| Seaweed, $n$ (%) | 10 (43.5) | 32 (51.6)    | 0.627|
| Pickles, $n$ (%) | 11 (47.8) | 33 (53.2)    | 0.808|
| Mushrooms, $n$ (%) | 7 (30.4) | 38 (61.3)    | 0.015|
| Fruit, $n$ (%)  | 14 (60.9)    | 43 (69.4)    | 0.604|
| Beef and pork, $n$ (%) | 13 (56.5) | 46 (74.2)    | 0.184|
| Chicken, $n$ (%) | 10 (43.5) | 39 (62.9)    | 0.140|
| Soybeans and soybean-derived foods, $n$ (%) | 7 (30.4) | 39 (62.9)    | 0.013|
| Milk and dairy products, $n$ (%) | 14 (60.9) | 41 (66.1)    | 0.799|
| Green tea, $n$ (%) | 11 (47.8) | 41 (66.1)    | 0.140|
| Coffee, $n$ (%)  | 10 (43.5)    | 44 (71.0)    | 0.024|
| **Cooking method** |          |              |      |
| Boiling, $n$ (%) | 18 (78.3)    | 35 (56.5)    | 0.081|
| Steaming, $n$ (%) | 7 (30.4) | 22 (35.5)    | 0.799|
| Raw, $n$ (%)     | 12 (52.2)    | 41 (66.1)    | 0.314|
| Deep-frying, $n$ (%) | 10 (43.5) | 21 (33.9)    | 0.454|
| Frying, $n$ (%)  | 12 (52.2)    | 41 (66.1)    | 0.314|
| Use of soup stock, $n$ (%) | 14 (60.9) | 58 (93.6)    | 0.001|
Use of fermented seasoning, $n$ (%) | 18 (78.3) | 57 (91.9) | 0.125

The Wilcoxon rank-sum test and the $\chi^2$ test were used.
Table 2. Comparison of the characteristics of participants with JDI\textsubscript{12} scores above or below the median value

|                      | High JDI\textsubscript{12} | Low JDI\textsubscript{12} | P  |
|----------------------|-----------------------------|-----------------------------|----|
|                      | \((n = 47)\)                | \((n = 38)\)                |    |
| **Demographic factor** |                             |                             |    |
| Age, years           | 75, 68–80                   | 77, 72–81                   | 0.428 |
| Female sex, \(n\) (%)| 22 (46.8)                   | 30 (79.0)                   | 0.004 |
| Education, years     | 12, 9–13                    | 12, 9–12                    | 0.300 |
| Body mass index, kg/m\textsuperscript{2} | 22.4, 20.6–24.5 | 22.8, 20.6–24.8 | 0.630 |
| Systolic BP, mmHg    | 151, 128–1,632              | 143, 123–162                | 0.221 |
| Diastolic BP, mmHg   | 83, 72–90                   | 77, 70–86                   | 0.128 |
| **Risk factor**      |                             |                             |    |
| Hypertension, \(n\) (%)| 28 (59.6)                   | 25 (65.8)                   | 0.654 |
| Diabetes mellitus, \(n\) (%)| 6 (12.8)        | 5 (13.2)                   | 1.000 |
| Dyslipidemia, \(n\) (%)| 21 (44.7)                   | 23 (60.5)                   | 0.191 |
| IHD, \(n\) (%)       | 5 (10.6)                    | 6 (15.8)                    | 0.530 |
| Stroke, \(n\) (%)    | 5 (10.6)                    | 3 (7.9)                     | 0.726 |
| CKD, \(n\) (%)       | 15 (31.9)                   | 14 (36.8)                   | 0.653 |
| Smoking habit, \(n\) (%)| 13 (27.7)                  | 7 (18.4)                    | 0.441 |
| Alcohol consumption, \(n\) (%)| 21 (44.7)       | 13 (34.2)                   | 0.378 |
| APOE \(\varepsilon\)4 carrier, \(n\) (%)| 10 (21.3)       | 11 (29.0)                   | 0.456 |
| Dementia, \(n\) (%)  | 7 (14.9)                    | 16 (42.1)                   | 0.007 |
| Frailty, \(n\) (%)   | 5 (10.6)                    | 8 (21.1)                    | 0.232 |
| **Comprehensive geriatric assessment** |                             |                             |    |
| Barthel index         | 100, 100–100                | 100, 99–100                 | 0.059 |
| IADL impairment, \(n\) (%)| 15 (31.9)                  | 18 (47.4)                   | 0.182 |
| DBDS                 | 5, 3–11                     | 9, 4–16                     | 0.225 |
| GDS                  | 2, 1–4                      | 4, 2–5                      | 0.057 |
### ZBI

|   | Mean | Min–Max | Mean | Min–Max | p-value |
|---|------|---------|------|---------|---------|
|   | 6.3  | 3–16    | 12.5 | 5–22    | 0.085   |

### MNA-SF

|   | Mean | Min–Max | Mean | Min–Max | p-value |
|---|------|---------|------|---------|---------|
|   | 13.1 | 11–14   | 12.1 | 11–13   | 0.269   |

### Cognitive function

#### MMSE

|   | Mean | Min–Max | Mean | Min–Max | p-value |
|---|------|---------|------|---------|---------|
|   | 26.2 | 22–29   | 24.9 | 19–28   | 0.066   |

#### CDR-GB

|   | 0, n (%) | 12 (25.5) | 8 (21.1) | 0.252 |
|---|----------|-----------|----------|-------|
|   | 0.5, n (%) | 33 (68.1) | 17 (44.7) | 0.025 |
|   | ≥1, n (%) | 3 (6.4) | 13 (34.2) | 0.025 |

#### ADAS-cog

|   | Mean | Min–Max | Mean | Min–Max | p-value |
|---|------|---------|------|---------|---------|
|   | 8.0  | 5.0–14.0 | 11.3 | 6.9–16.7 | 0.085 |

#### RCPM

|   | Mean | Min–Max | Mean | Min–Max | p-value |
|---|------|---------|------|---------|---------|
|   | 29.0 | 24–32   | 28.0 | 24–30   | 0.431   |

#### FAB

|   | Mean | Min–Max | Mean | Min–Max | p-value |
|---|------|---------|------|---------|---------|
|   | 11.0 | 9–14    | 11.0 | 9–13    | 0.984   |

#### LM-WMSR I

|   | Mean | Min–Max | Mean | Min–Max | p-value |
|---|------|---------|------|---------|---------|
|   | 11.0 | 5–18    | 7.0  | 3–13    | 0.048   |

#### LM-WMSR II

|   | Mean | Min–Max | Mean | Min–Max | p-value |
|---|------|---------|------|---------|---------|
|   | 5.0  | 0–12    | 1.0  | 0–6     | 0.033   |

### Brain MRI finding

#### SLI, n (%)

|   | Mean | Min–Max | Mean | Min–Max | p-value |
|---|------|---------|------|---------|---------|
|   | 6 (12.8) | 3 (7.9) | 0.725 |

#### WMH, n (%)

|   | Mean | Min–Max | Mean | Min–Max | p-value |
|---|------|---------|------|---------|---------|
|   | 8 (17.0) | 14 (36.8) | 0.048 |

#### CMB, n (%)

|   | Mean | Min–Max | Mean | Min–Max | p-value |
|---|------|---------|------|---------|---------|
|   | 9 (19.2) | 6 (15.8) | 0.779 |

#### EPVS, n (%)

|   | Mean | Min–Max | Mean | Min–Max | p-value |
|---|------|---------|------|---------|---------|
|   | 8 (17.0) | 10 (26.3) | 0.424 |

### SVD score

|   | Mean | Min–Max | Mean | Min–Max | p-value |
|---|------|---------|------|---------|---------|
|   | 1, 0–1 | 0, 0–2 | 0.506 |

#### VSRAD

|   | Mean | Min–Max | Mean | Min–Max | p-value |
|---|------|---------|------|---------|---------|
|   | 0.80 | 0.57–1.30 | 1.09 | 0.78–2.08 | 0.087 |

### SPECT

#### Low blood flow*

|   | Mean | Min–Max | Mean | Min–Max | p-value |
|---|------|---------|------|---------|---------|
|   | 30 (65.2) | 23 (62.2) | 0.821 |

### Arterial stiffness

#### Ankle brachial index

|   | Mean | Min–Max | Mean | Min–Max | p-value |
|---|------|---------|------|---------|---------|
|   | 1.11 | 1.04–1.14 | 1.12 | 1.05–1.16 | 0.553 |

#### Pulse wave velocity, m/s

|   | Mean | Min–Max | Mean | Min–Max | p-value |
|---|------|---------|------|---------|---------|
|   | 18.6 | 15.8–21.9 | 17.2 | 14.6–19.8 | 0.159 |

### Laboratory finding

#### Total protein, g/dL

|   | Mean | Min–Max | Mean | Min–Max | p-value |
|---|------|---------|------|---------|---------|
|   | 7.2  | 6.9–7.6 | 7.3  | 6.9–7.6 | 0.814 |

#### Albumin, g/dL

|   | Mean | Min–Max | Mean | Min–Max | p-value |
|---|------|---------|------|---------|---------|
|   | 4.3  | 4.0–4.5 | 4.3  | 4.0–4.4 | 0.552 |
| Variable          | Mean ± SD | Median (IQR) | p-value |
|-------------------|-----------|--------------|---------|
| CRP, mg/dL        | 0.06      | 0.02–0.18    | 0.505   |
| eGFR, mL/min/1.73 m² | 70.4    | 55.8–74.1    | 0.340   |
| HbA1c, %          | 5.8       | 5.6–6.2      | 0.550   |

Continuous, ordinal, and categorical variables are expressed as the mean ± standard deviation, median and interquartile range, or frequency or proportion (percentage), respectively. The Wilcoxon rank-sum test and the $\chi^2$ test were used.

*Low blood flow in the area of the posterior cingulate gyrus and/or the precuneus.

Abbreviations: JDI, Japanese dietary index; BP, blood pressure; IHD, ischemic heart disease; CKD, chronic kidney disease; ApoE, apolipoprotein E; IADL, instrumental activities of daily living; DBDS, Dementia Behavior Disturbance Scale; GDS, Geriatric Depression Scale; ZBI, Zarit Caregiver Burden Interview; MNA-SF, Mini-Nutritional Assessment-Short Form; MMSE, Mini-Mental State Examination; CDR-GB, Clinical Dementia Rating Global Score; CDR-SB, Clinical Dementia Rating-Sum of Boxes; ADAS-cog, Alzheimer’s Disease Assessment Scale-Cognitive Subscale; RCPM, Raven’s Colored Progressive Matrices; FAB, Frontal Assessment Battery; LM-WMSR, Logical Memory subtests I and II of the Wechsler Memory Scale-Revised; SLI, silent lacunar infarct; WMH, white matter hyperintensity; CMB, cerebral microbleeds; EPVS, enlarged perivascular space; SVD, small vessel disease; VSRAD, voxel-based specific regional analysis system for Alzheimer’s disease; SPECT, single-photon emission computed tomography; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate.
Table 3. Comparison of the gut microbiome and fecal microbial metabolite concentrations of participants with JDI<sub>12</sub> scores above or below the median value

| Gut microbiome | High JDI<sub>12</sub> (n = 47) | Low JDI<sub>12</sub> (n = 38) | P    |
|----------------|--------------------------------|-----------------------------|------|
| **Enterotype I, n (%)** | 15 (34.2) | 13 (34.1) | 0.716 |
| **Enterotype II, n (%)** | 3 (6.4) | 1 (2.6) | 0.147 |
| **Enterotype III, n (%)** | 29 (61.7) | 24 (63.2) | 0.05  |
| **F/B ratio** | 1.50, 0.82–2.70 | 1.84, 1.11–3.12 | 0.431 |

Metabolite

| Metabolite | High JDI<sub>12</sub> (n = 47) | Low JDI<sub>12</sub> (n = 38) | P    |
|------------|--------------------------------|-----------------------------|------|
| Ammonia, mg/g | 0.64, 0.37–0.98 | 0.58, 0.24–0.94 | 0.622 |
| Succinic acid, mg/g | 0.03, 0.03–0.10 | 0.03, 0.03–0.44 | 0.318 |
| Lactic acid, mg/g | 0.03, 0.03–0.10 | 0.03, 0.03–0.58 | 0.863 |
| Formic acid, mg/g | 0.05, 0.05–0.05 | 0.05, 0.05–0.05 | 0.282 |
| Acetic acid, mg/g | 2.27, 0.03–6.09 | 2.91, 0.03–6.84 | 0.741 |
| Propionic acid, mg/g | 0.23, 0.03–1.51 | 0.84, 0.03–2.46 | 0.206 |
| Iso-butyric acid, mg/g | 0.06, 0.03–0.19 | 0.07, 0.03–0.15 | 0.669 |
| n-butyric acid, mg/g | 0.13, 0.03–0.86 | 0.29, 0.03–0.88 | 0.347 |
| Iso-valeric acid, mg/g | 0.03, 0.03–0.38 | 0.03, 0.03–0.25 | 0.863 |
| n-valeric acid, mg/g | 0.24, 0.03–1.95 | 0.17, 0.03–2.61 | 0.639 |
| Phenol, μg/g | 1.02, 0.0003–1.93 | 1.16, 0.0003–2.12 | 0.495 |
| P-cresol, μg/g | 0.32, 0.0003–118.07 | 0.24, 0.0003–15.27 | 0.213 |
| 4-Ethylphenol, μg/g | 0.26, 0.0003–0.91 | 0.0003, 0.0003–0.66 | 0.110 |
| Indoles, μg/g | 1.79, 0.14–25.57 | 1.06, 0.0003–22.53 | 0.728 |
| Skatole, μg/g | 0.11, 0.0003–5.79 | 0.0003, 0.0003–0.17 | 0.033 |

The Wilcoxon rank-sum test and the χ<sup>2</sup> test were used.

Table 4. Multivariable logistic regression analyses for the presence of dementia
|                | OR  | 95% CI      | P    |
|----------------|-----|-------------|------|
| **High JDI\textsubscript{9} score (vs. Low score) * |     |             |      |
| Model 1        | 0.41| 0.15-1.08   | 0.070|
| Model 2        | 0.48| 0.17-1.38   | 0.175|
| Model 3        | 0.59| 0.18-1.94   | 0.384|
| Model 4        | 0.36| 0.12-1.03   | 0.057|
| **High JDI\textsubscript{12} score (vs. Low score) * |     |             |      |
| Model 1        | 0.24| 0.08-0.65   | 0.005|
| Model 2        | 0.33| 0.11-0.97   | 0.043|
| Model 3        | 0.22| 0.07-0.66   | 0.006|
| Model 4        | 0.10| 0.01-0.45   | 0.002|
| **High rJDI\textsubscript{12} score (vs. Low score) * |     |             |      |
| Model 1        | 0.29| 0.09-0.80   | 0.016|
| Model 2        | 0.36| 0.11-1.06   | 0.064|
| Model 3        | 0.34| 0.10-1.10   | 0.072|
| Model 4        | 0.34| 0.07-1.32   | 0.120|

*Allocated to two groups according to their JDI: a high JDI\textsubscript{12} group (above the median value) and a low JDI group (below the median value).

Abbreviations: OR, odds ratio; CI, confidence interval; JDI, Japanese dietary index. The dependent variable was the presence of dementia. JDI\textsubscript{9}: conventional JDI score, which comprised seven beneficial components (“rice”, “miso”, “fish and shellfish”, “green and yellow vegetables”, “seaweed”, “pickles”, and “green tea”), and two less beneficial components (“beef and pork” and “coffee”); 0–9 points. JDI\textsubscript{12}: modified JDI score, comprising the JDI\textsubscript{9} components and three additional beneficial components (“soybeans and soybean-derived foods”, “fruit”, and “mushrooms”); 0–12 points. r-JDI\textsubscript{12}: revised JDI\textsubscript{12} score, in which one less beneficial component (“coffee”) in the JDI\textsubscript{12} was changed to a
beneficial component, such that these became “rice”, “miso”, “fish and shellfish”, “green and yellow vegetables”, “seaweed”, “pickles”, “green tea” and “coffee”; and there was just one less beneficial component (“beef and pork”), making it more consistent with the modern Japanese diet; 0–12 points.

Model 1: univariate analyses. Model 2: adjusted for age, sex. Model 3: backward stepwise multivariable logistic regression analyses, which were adjusted for the model 2 factors, years of education, and risk factors (hypertension, dyslipidemia, diabetes mellitus, ischemic heart disease, chronic kidney disease, smoking, alcohol consumption, and ApoE). Model 4: backward stepwise multivariable logistic regression analyses adjusted for the factors in model 3, plus enterotype I, silent lacunar infarct, white matter hyperintensity, cerebral microbleeds, enlarged perivascular space, score of the voxel-based specific regional analysis system for Alzheimer’s disease, single-photon emission-computed tomography findings (presence or absence of low blood flow in the area of the posterior cingulate gyrus and/or precuneus), ankle brachial index, and pulse wave velocity.

Figures
Comparison of the Japanese diet indices (JDI9, JDI12, and rJDI12) in participants with and without dementia. The x-axis shows the presence or absence of dementia and the y-axis the JDI score. * P < 0.05 and ** P < 0.01, according to the Wilcoxon rank-sum test. JDI9: conventional JDI score; JDI12: modified JDI score, including three additional components (soybeans and soybean-derived foods, fruit, and mushrooms); rJDI12: revised JDI12 score, in which one less beneficial component (coffee) in the JDI12 was redefined as a beneficial component. The rJDI12 score more clearly shows the difference between participants with and without dementia than the JDI9 and JDI12 scores.
Prevalences of dementia, according to the tertiles of Japanese dietary index scores (JDI9, JDI12, and rJDI12) The x-axis shows the tertiles of the Japanese diet indices (JDI) and the y-axis the prevalence of dementia (%). rJDI12 more clearly shows the difference among participants categorized according to the tertiles of the JDI score than JDI9 and JDI12.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- Supplementaryfile0219.docx